Linarol-M Tablet 2.5 mg+1000 mg is a combination oral antidiabetic medication containing Linagliptin (2.5 mg) and Metformin Hydrochloride (1000 mg). It is formulated for adults with type 2 diabetes mellitus who require effective glycemic control and are not adequately managed by diet, exercise, or monotherapy with either Linagliptin or Metformin.

This dual-action therapy offers comprehensive blood sugar management. Linagliptin, a DPP-4 inhibitor, enhances glucose-dependent insulin secretion and reduces glucagon release, while Metformin improves insulin sensitivity in peripheral tissues and decreases hepatic glucose production. Together, these effects provide effective control of fasting and postprandial blood glucose levels, helping to prevent complications associated with chronic hyperglycemia.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Mechanism of Action

Linarol-M Tablet 2.5 mg+1000 mg works through the complementary actions of its two components:

• Linagliptin (2.5 mg): Inhibits the DPP-4 enzyme, prolonging the action of incretin hormones (GLP-1 and GIP), which increase insulin release when blood glucose is elevated and suppress glucagon secretion, lowering hepatic glucose output.

• Metformin (1000 mg): Enhances insulin sensitivity in muscle and adipose tissue, reduces hepatic gluconeogenesis, and promotes peripheral glucose utilization.

• Synergistic effect: The combination ensures sustained glycemic control, minimizes postprandial blood sugar spikes, and helps maintain stable blood glucose throughout the day.

This formulation is particularly suitable for patients requiring stronger glycemic control than lower-dose combination tablets.

Indications

Linarol-M Tablet 2.5 mg+1000 mg is indicated for:

• Type 2 diabetes mellitus: For patients whose blood sugar is not adequately controlled with diet, exercise, or monotherapy.

• Combination therapy: Can be used alongside other oral antidiabetic agents or insulin under medical supervision.

• Postprandial glucose management: Helps prevent high blood sugar spikes after meals and supports overall glycemic stability.

It is not suitable for type 1 diabetes, diabetic ketoacidosis, or patients with severe renal or hepatic impairment.

Dosage and Administration

• The usual dose is 1 tablet once or twice daily, taken with meals to reduce gastrointestinal side effects associated with Metformin.

• Swallow the tablet whole with water; do not crush or chew.

• Dosage adjustment may be required based on blood glucose monitoring, HbA1c, and clinical response, under medical supervision.

• Regular monitoring of fasting and postprandial glucose, as well as HbA1c, is recommended to assess treatment effectiveness.

• Patients should continue following a balanced diet, exercise regimen, and lifestyle modifications for optimal results.

Precautions

• Use with caution in patients with renal or hepatic impairment, as Metformin may rarely cause lactic acidosis.

• Hypoglycemia may occur, especially if used with other antidiabetic medications, skipped meals, or excessive physical activity.

• Inform your physician about any cardiovascular disease, pancreatitis, or history of lactic acidosis.

• Alcohol consumption should be minimized, as it may increase the risk of hypoglycemia or lactic acidosis.

• Consult your doctor before use in pregnancy or breastfeeding.

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Possible Side Effects

Common side effects may include:

• Hypoglycemia (dizziness, sweating, fatigue, confusion)

• Gastrointestinal disturbances: nausea, vomiting, diarrhea, or mild abdominal discomfort

• Headache

• Joint pain

Rare but serious side effects include:

• Pancreatitis (severe abdominal pain, nausea, vomiting)

• Severe allergic reactions (rash, swelling, difficulty breathing)

• Lactic acidosis (very rare)

Seek immediate medical attention if severe or persistent symptoms occur.

Storage

Store below 30°C in a dry, cool place away from direct sunlight and moisture. Keep out of reach of children.

Linarol-M Tablet 2.5 mg+1000 mg provides effective dual-action therapy for type 2 diabetes, combining Linagliptin and Metformin to maintain stable blood glucose, enhance insulin function, and reduce long-term complications under medical supervision.